Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2023-02-14 Major Shareholding Noti…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an FDA approval event for a plasma collection facility and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is relatively short (3342 characters) and serves as an announcement of a specific event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-02-08 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which relates to the Results of Operations and Financial Condition, and it includes a press release announcing preliminary unaudited quarterly and full year financial results and guidance. The document does not contain full financial statements or detailed analysis but rather a summary announcement of financial results. The length is 3474 characters, which is relatively short and consistent with a current report or earnings release announcement. Given that it announces preliminary financial results and guidance, this fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the appropriate classification is Earnings Release (ER).
2023-01-17 English
Director's Dealing 2023
Director's Dealing
2023-01-07 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.